tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ASND Stock Latest News

Ascendis Pharma Posts Positive Phase 2 Results for Once-Weekly TransCon hGH in Turner Syndrome
Company AnnouncementsAscendis Pharma Posts Positive Phase 2 Results for Once-Weekly TransCon hGH in Turner Syndrome
6d ago
6K
ASND
Ascendis Pharma’s TransCon shows efficacy and safety in Turner Syndrome
PremiumThe Fly
Ascendis Pharma’s TransCon shows efficacy and safety in Turner Syndrome
6d ago
ASND
Ascendis Pharma Reports Two-Year Data Showing Sustained Benefits of YUVIWEL in Children With Achondroplasia
PremiumCompany Announcements
Ascendis Pharma Reports Two-Year Data Showing Sustained Benefits of YUVIWEL in Children With Achondroplasia
7d ago
6K
ASND
Ascendis Pharma assumed with a Buy at Jefferies
PremiumThe Fly
Ascendis Pharma assumed with a Buy at Jefferies
7d ago
ASND
Ascendis Pharma announces new data from Navepegritide trial
PremiumThe Fly
Ascendis Pharma announces new data from Navepegritide trial
7d ago
ASND
Ascendis Pharma: Durable Endocrine Franchise Growth and Emerging Pipeline Upside Support Buy Rating
PremiumRatingsAscendis Pharma: Durable Endocrine Franchise Growth and Emerging Pipeline Upside Support Buy Rating
7d ago
ASND
Ascendis Pharma price target raised to $332 from $325 at Stifel
Premium
The Fly
Ascendis Pharma price target raised to $332 from $325 at Stifel
19d ago
ASND
Ascendis Pharma price target raised to $275 from $250 at RBC Capital
Premium
The Fly
Ascendis Pharma price target raised to $275 from $250 at RBC Capital
20d ago
ASND
Ascendis Pharma Wins FDA Accelerated Approval for YUVIWEL in Pediatric Achondroplasia
PremiumCompany Announcements
Ascendis Pharma Wins FDA Accelerated Approval for YUVIWEL in Pediatric Achondroplasia
21d ago
6K
ASND
Ascendis Pharma trading resumes
PremiumThe Fly
Ascendis Pharma trading resumes
23d ago
ASND
Ascendis Pharma announces FDA approval of Yuviwel
PremiumThe Fly
Ascendis Pharma announces FDA approval of Yuviwel
23d ago
ASND
Ascendis Pharma trading halted, news pending
PremiumThe Fly
Ascendis Pharma trading halted, news pending
24d ago
ASND
Ascendis Pharma Sets March 23 AGM to Approve 2025 Results, Board Changes and Buyback Mandate
PremiumCompany AnnouncementsAscendis Pharma Sets March 23 AGM to Approve 2025 Results, Board Changes and Buyback Mandate
28d ago
6K
ASND
Ascendis Pharma Earnings Call Highlights Growth Momentum
Premium
Company Announcements
Ascendis Pharma Earnings Call Highlights Growth Momentum
1M ago
ASND
Ascendis Pharma price target raised to $273 from $240 at Wedbush
Premium
The Fly
Ascendis Pharma price target raised to $273 from $240 at Wedbush
1M ago
ASND
Ascendis Pharma price target raised to $262 from $246 at Oppenheimer
PremiumThe Fly
Ascendis Pharma price target raised to $262 from $246 at Oppenheimer
1M ago
ASND
Ascendis Pharma price target raised to $325 from $256 at Stifel
PremiumThe Fly
Ascendis Pharma price target raised to $325 from $256 at Stifel
1M ago
ASND
Ascendis Pharma price target raised to $256 from $250 at Morgan Stanley
PremiumThe Fly
Ascendis Pharma price target raised to $256 from $250 at Morgan Stanley
1M ago
ASND
Ascendis Pharma: Strong Yorvipath Momentum, Pipeline Upside, and Raised DCF Assumptions Underpin Buy Rating and $260 Target
PremiumRatings
Ascendis Pharma: Strong Yorvipath Momentum, Pipeline Upside, and Raised DCF Assumptions Underpin Buy Rating and $260 Target
1M ago
ASND
Ascendis Pharma: Accelerating Commercial Momentum and Pipeline Execution Support Higher Target and Buy Rating
PremiumRatingsAscendis Pharma: Accelerating Commercial Momentum and Pipeline Execution Support Higher Target and Buy Rating
1M ago
ASND
ASND: Strong Yorvipath Momentum and Pipeline Catalysts Underpin Buy Rating and Long‑Term Upside
Premium
Ratings
ASND: Strong Yorvipath Momentum and Pipeline Catalysts Underpin Buy Rating and Long‑Term Upside
1M ago
ASND
Ascendis Pharma Posts Strong 2025 Results as YORVIPATH Drives Growth and TransCon Pipeline Advances
Premium
Company Announcements
Ascendis Pharma Posts Strong 2025 Results as YORVIPATH Drives Growth and TransCon Pipeline Advances
1M ago
6K
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >